论文部分内容阅读
目的探讨钙拮抗剂抑制肝纤维化改善门脉高动力循环的作用机制。方法分三组测定肝组织中一氧化氮合酶 (NOS)活性和血清中一氧化氮 (NO) ;观察门静脉血流量 (PVF)、门静脉压力(PVP)、门静脉阻力 (PVR)及肝脏病理学改变。结果钙拮抗剂汉防己甲素显著抑制NOS活性和NO生成 ,明显降低PVP和PVF ,病理切片显示汉防己甲素明显防止肝细胞坏死 ,阻止肝纤维化发展。结论抑制NOS活性和NO生成是钙拮抗剂防治肝硬化门脉高压症的主要作用机理
Objective To investigate the mechanism of calcium antagonist inhibiting hepatic fibrosis and improving portal hyperdynamic circulation. Methods The activity of nitric oxide synthase (NOS) and nitric oxide (NO) in liver tissue were measured in three groups. The portal vein blood flow (PVF), portal pressure (PVP), portal vein resistance (PVR) and liver pathology change. Results Tetrandrine, a calcium antagonist, significantly inhibited NOS activity and NO production, and significantly decreased PVP and PVF. Pathological sections showed that tetrandrine prevented hepatocellular necrosis and prevented the development of hepatic fibrosis. Conclusions Inhibition of NOS activity and NO production are the main mechanisms by which calcium antagonists prevent and treat cirrhotic portal hypertension